Lakefront Biotherapeutics (LKFT) Payables (2014 - 2026)
Lakefront Biotherapeutics (LKFT) posted quarterly Payables of $112.1 million for Q1 2026, down 36.91% year-over-year from $177.7 million in Q1 2025, and down 7.96% quarter-over-quarter from $121.8 million in Q4 2025.
Lakefront Biotherapeutics (LKFT) Payables (2014 - 2026) Analysis & Trends
Lakefront Biotherapeutics (LKFT) has reported Payables for 13 consecutive years, with $112.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Payables fell 36.91% year-over-year to $112.1 million; the TTM figure through Mar 2026 stood at $112.1 million (down 36.91% YoY), while the FY2025 annual figure was $121.8 million, up 15.29% from the prior year.
- Payables declined to $112.1 million in Q1 2026 per LKFT's latest filing, from $121.8 million in the prior quarter.
- Across five years, Payables topped out at $177.7 million in Q1 2025 and bottomed at $105.7 million in Q4 2024.
- Historically, Payables has averaged $139.9 million across 5 years, with a median of $145.5 million in 2023.
- Annual changes were most pronounced in 2025 — Payables climbed 15.29% — and 2026, when it sank 36.91%.
- Lakefront Biotherapeutics' Payables stood at $151.7 million in 2022, then dropped by 4.1% to $145.5 million in 2023, then retreated by 27.37% to $105.7 million in 2024, then climbed by 15.29% to $121.8 million in 2025, then fell by 7.96% to $112.1 million in 2026.
- Business Quant data shows LKFT's Payables at $112.1 million in Q1 2026, $121.8 million in Q4 2025, and $117.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.52 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 88.42 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 470.30 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.05 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 35.57 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 108.02 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 428.93 Mn |
| 10 | Lakefront Biotherapeutics | 1.81 Bn | -1.68 Bn | 1.97 Mn | 112.12 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 112.12 Mn |
| Dec 31, 2025 | 121.81 Mn |
| Sep 30, 2025 | 117.65 Mn |
| Jun 30, 2025 | 150.75 Mn |
| Mar 31, 2025 | 177.71 Mn |
| Dec 31, 2024 | 105.66 Mn |
| Sep 30, 2024 | 127.24 Mn |
| Mar 31, 2024 | 158.12 Mn |
| Dec 31, 2023 | 145.47 Mn |
| Sep 30, 2023 | 131.86 Mn |
| Mar 31, 2023 | 167.39 Mn |
| Dec 31, 2022 | 151.69 Mn |
| Mar 31, 2022 | 151.14 Mn |
| Dec 31, 2021 | 157.44 Mn |
| Jun 30, 2021 | 182.71 Mn |
| Dec 31, 2020 | 209.31 Mn |
| Jun 30, 2020 | 197.64 Mn |
| Mar 31, 2020 | 187.09 Mn |
| Dec 31, 2019 | 158.77 Mn |
| Sep 30, 2019 | 173.87 Mn |